Equitable Holdings Inc. Makes New Investment in Revolution Medicines, Inc. $RVMD

Equitable Holdings Inc. acquired a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 5,140 shares of the company’s stock, valued at approximately $963,000.

Other large investors have also made changes to their positions in the company. Public Employees Retirement System of Ohio acquired a new stake in shares of Revolution Medicines during the 2nd quarter worth about $14,496,000. Capstone Investment Advisors LLC bought a new stake in Revolution Medicines during the second quarter worth about $1,348,000. Seven Fleet Capital Management LP grew its stake in Revolution Medicines by 199.6% during the second quarter. Seven Fleet Capital Management LP now owns 242,029 shares of the company’s stock worth $45,327,000 after buying an additional 161,237 shares during the last quarter. Corient Private Wealth LP acquired a new stake in shares of Revolution Medicines during the second quarter worth approximately $1,523,000. Finally, Artia Global Partners LP bought a new position in shares of Revolution Medicines in the second quarter valued at approximately $34,720,000. Institutional investors own 94.34% of the company’s stock.

Get Revolution Medicines alerts:

Trending Headlines about Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: FDA approval creates a major commercial opportunity. Rasonque became the first broad RAS-targeted therapy approved for metastatic pancreatic cancer and Revolution Medicines’ first marketed product. The approval arrived roughly five weeks after filing through the FDA’s national priority voucher program. In the pivotal RASolute 302 trial, the treatment reportedly nearly doubled survival outcomes, supporting expectations for rapid adoption. RVMD Secures FDA Win
• Positive Sentiment: Analysts raised their valuations. Guggenheim increased its price target to $275 from $240 with a Buy rating, while HC Wainwright maintained a Buy rating and a $280 target. Analysts cited potential peak sales of approximately $11.5 billion, and RBC viewed the planned launch as comparatively rapid. Revolution Medicines FDA Approval and Peak Sales
• Neutral Sentiment: Much of the good news may already be reflected in the stock. RVMD recently reached an all-time high above $224 and its market capitalization approached $47 billion. Commentary suggests investors had already priced in a successful approval, limiting additional upside from the announcement. Revolution Medicines Valuation Analysis
• Negative Sentiment: Profit-taking and risk concerns are weighing on shares. Despite the “transformative” approval, the stock is facing a weekly decline as investors lock in gains after a more-than-fivefold rally. Revolution Medicines remains unprofitable, with analysts forecasting negative EPS for 2027, although losses are expected to narrow to $6.86 per share for the full year. Revolution Medicines Shares Despite FDA Approval

Wall Street Analyst Weigh In

RVMD has been the topic of several recent analyst reports. Piper Sandler boosted their target price on Revolution Medicines to $172.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Mizuho raised their price target on Revolution Medicines from $185.00 to $215.00 and gave the company an “outperform” rating in a report on Monday, July 6th. Raymond James Financial restated a “strong-buy” rating and set a $248.00 target price on shares of Revolution Medicines in a report on Thursday. Needham & Company LLC raised their target price on Revolution Medicines from $236.00 to $240.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Wolfe Research reaffirmed an “outperform” rating and issued a $220.00 price target on shares of Revolution Medicines in a report on Monday, August 10th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Revolution Medicines currently has a consensus rating of “Moderate Buy” and a consensus price target of $198.89.

Get Our Latest Stock Analysis on RVMD

Insider Transactions at Revolution Medicines

In other Revolution Medicines news, insider Mark A. Goldsmith sold 80,000 shares of the stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $209.20, for a total value of $16,736,000.00. Following the transaction, the insider owned 267,330 shares of the company’s stock, valued at approximately $55,925,436. This represents a 23.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Sushil Patel sold 5,580 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $187.99, for a total value of $1,048,984.20. Following the transaction, the director owned 21,656 shares in the company, valued at approximately $4,071,111.44. This trade represents a 20.49% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 212,497 shares of company stock valued at $38,206,486. Corporate insiders own 7.60% of the company’s stock.

Revolution Medicines Stock Down 6.0%

Shares of NASDAQ RVMD opened at $207.88 on Friday. The firm has a market capitalization of $44.56 billion, a PE ratio of -23.57 and a beta of 1.39. The company has a current ratio of 11.38, a quick ratio of 11.38 and a debt-to-equity ratio of 0.40. Revolution Medicines, Inc. has a 1 year low of $37.56 and a 1 year high of $224.31. The firm’s 50-day moving average is $193.33 and its 200-day moving average is $148.59.

Revolution Medicines (NASDAQ:RVMD – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same period last year, the company earned ($1.31) EPS. Equities analysts expect that Revolution Medicines, Inc. will post -8.85 EPS for the current year.

Revolution Medicines Profile

(Free Report)

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

Featured Stories

• Five stocks we like better than Revolution Medicines
• From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
• These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
• Venture Into High-Volatility Corners of the Market With These 3 ETFs
• 3 Retail Stocks to Watch After a Big Consumer Earnings Week

Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report).

Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.